Abstract:Objective:To investigate the incidence of alopecia after pediatric liver transplantation and its related risk factors.Methods:A retrospective case-control study was used. The subjects were children who underwent liver transplantation in the Second Affiliated Hospital, Zhejiang University School of Medicine from July 2019 to December 2020. The information such as gender, age, primary disease, preoperative body mass index (BMI), graft-to-recipient weight ratio (GRWR), albumin, hemoglobin and total bilirubin before the operation, and blood concentration of tacrolimus were collected from the hospital information system. The follow-up content included whether there was alopecia after surgery, the site of alopecia, the degree of alopecia, the occurrence time and recovery time of alopecia after surgery. The children were divided into alopecia group and non-alopecia group according to whether there were alopecia, and the related indicators were analyzed by univariate analysis, and the results were expressed by odds ratio ( OR) and its 95% confidence interval ( CI). Results:A total of 40 children who met the inclusion criteria were collected, including 20 males and 20 females. The median age at surgery was 20(11, 43) months and the age ranged from 5 months to 13 years. The BMI was (17.1±2.1) kg/m 2 and the GRWR was (2.6±0.7)%. The serum TBil, blood albumin, and hemoglobin before the operation were 120 (27, 191) μmol/L, (33±5) g/L, and (100±14) g/L, respectively. The blood concentration of tacrolimus was (10.37±2.15) μg/L within one month after the operation. Among the 40 children, 17 developed alopecia, including 8 males and 9 females. The severity of alopecia was S 1 in 16 cases and S 2 in 1 case. There were 14 cases of local hair loss and 3 cases of general hair loss. The occurrence time of alopecia in all 17 patients was distributed from 4 days to 9 months after operation, including 15 cases within 1 month after operation, and 2 cases 3 and 9 months after operation, respctively. All patients did not receive symptomatic treatment for alopecia and returned to normal within 1 year after the operation. Univariate analysis showed that low preoperative albumin level and high concentration of tacrolimus within one month after surgery were risk factors for alopecia after pediatric liver transplantation [ (31±4) g/L vs. (34±5) g/L, OR=0.83, 95% CI: 0.71-0.98, P=0.026; (12.0±2.1) μg/L vs. (9.2± 1.2) μg/L, OR=2.80, 95% CI: 1.55-5.05, P=0.001]. Conclusion:Low preoperative albumin level and high concentration of tacrolimus within one month after surgery may be risk factors for alopecia in children after liver transplantation.

Risk factors for post-transplant lymphoproliferative disorder after pediatric liver transplantation

Clinical analysis of posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: a report of 11 cases

[Early Diagnosis and Comprehensive Treatments of Post-Transplantation Lymphoproliferative Disorder after Pediatric Liver Transplantation].

Impact of EBV Infection and Immune Function Assay for Lymphoproliferative Disorder in Pediatric Patients after Liver Transplantation: A Single-Center Experience.

Diagnosis and Treatment of Post-Transplant Lymphoproliferative Disorder in Pediatric Liver Transplantation: a Report of 3 Cases

A preliminary study on the incidence and risk factors of alopecia after pediatric liver transplantation

Post-transplantation lymphoproliferative disorders of kidney in children: two cases report and literature review

[The Risk Factors of Post-Transplant Lymphoproliferative Disorders Following Haploidentical Hematopoietic Stem Cell Transplantation].

Post-transplantation Lymphoproliferative Disorder (PTLD): In the Liver Transplant Recipient

Imaging features and clinical analysis of posttransplantation lymphoproliferative disorders after liver transplantation in children

Epstein-Barr Virus–Related Post-Transplantation Lymphoproliferative Disorder after Unmanipulated Human Leukocyte Antigen Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical Outcomes

Clinical Analysis of Posttransplant Lymphoproliferative Disorder in Kidney Transplant Recipients and Hematopoietic Stem Cell Transplant Recipients Summary

Risk Factors Evaluation of Post-Transplant Lymphoproliferative Disorders after Allogeneic Haematopoietic Stem Cell Transplantation with Comparison Between Paediatric and Adult.

Transplantation for congenital heart disease is associated with an increased risk of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in children

Epstein–Barr virus‐associated post‐transplant lymphoproliferative disorders in pediatric transplantation: A prospective multicenter study in the United States

Post-transplant lymphoproliferative disorder associated Epstein-Barr virus DNAemia after liver transplantation in children: Experience from single center

The trend of Epstein-Barr virus DNA loads and CD8 + T lymphocyte numbers can predict the prognosis of pediatric liver transplant recipients with PTLD

Is Hepatitis B Virus Reactivation a Risk Factor in the Development of Posttransplant Lymphoproliferative Disorder Following Liver Transplantation?

[A Clinical Study of Lymphoproliferative Disorders Following Allogeneic Hematopoietic Stem Cell Transplantation].

A single-center experience of post-transplant lymphoproliferative disorder (PTLD) cases after pediatric liver transplantation: Incidence, outcomes, and association with food allergy

Clinical Study of Post-Transplantation Lymphoproliferative Diseases in Children with Acquired Aplastic Anemia After Allogeneic Hematopoietic Stem Cell Transplantation